Apellis Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03753U1060
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityAPLS / Apellis Pharmaceuticals, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership449,796 shares
Latest Disclosed Value $ 18,095,293
Squarepoint Ops LLC ownership in APLS / Apellis Pharmaceuticals, Inc.

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 449,796 shares of Apellis Pharmaceuticals, Inc. (US:APLS) valued at $18,095,293 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 192,156 shares of Apellis Pharmaceuticals, Inc.. This represents a change in shares of 134.08% during the quarter. The current value of the position is $18,455,130 USD.

Squarepoint Ops LLC has a history of taking positions in derivatives of the underlying security (APLS) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

APLS / Apellis Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 449,796 257,640 134.08 18,095 274.95 0.0213
2026-02-13 2025-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 192,156 139,322 263.70 4,827 303.85 0.0051
2025-11-14 2025-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 52,834 -276,558 -83.96 1,196 -79.04 0.0012
2025-08-27 2025-06-30 13F/A-1 APELLIS PHARMACEUTICALS COM 03753U106 329,392 -113,401 -25.61 5,702 -41.12 0.0059
2025-08-14 2025-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 329,392 -113,401 5,702 0.0059
2025-08-27 2025-03-31 13F/A-1 APELLIS PHARMACEUTICALS COM 03753U106 442,793 275,831 165.21 9,684 81.77 0.0118
2025-05-15 2025-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 442,793 275,831 9,684 0.0118
2025-02-14 2024-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 166,962 76,621 84.81 5,328 104.49 0.0053
2024-11-14 2024-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 90,341 29,083 47.48 2,605 10.90 0.0041
2024-08-14 2024-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 61,258 61,258 2,350 0.0039
2023-02-14 2022-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 0 -101,085 -100.00 0 -100.00
2022-11-14 2022-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 101,085 50,705 100.65 6,904 203.07 0.0348
2022-08-15 2022-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 50,380 31,082 161.06 2,278 132.21 0.0127
2022-05-16 2022-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 19,298 19,298 981 0.0042
2021-11-15 2021-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 0 -5,344 -100.00 0 -100.00
2021-08-16 2021-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 5,344 5,344 338 0.0013
2021-02-16 2020-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 0 -26,422 -100.00 0 -100.00
2020-11-16 2020-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 26,422 3,632 15.94 797 7.12 0.0107
2020-08-14 2020-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 22,790 12,799 128.11 744 177.61 0.0120
2020-05-15 2020-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 9,991 -10,368 -50.93 268 -56.98 0.0069
2020-02-14 2019-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 20,359 -23,538 -53.62 623 -41.06 0.0037
2019-11-14 2019-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 43,897 -20,103 -31.41 1,057 -34.83 0.0094
2019-08-14 2019-06-30 13F APELLIS PHARMACEUTICALS COM 03753U106 64,000 17,889 38.80 1,622 80.42 0.0158
2019-05-15 2019-03-31 13F APELLIS PHARMACEUTICALS COM 03753U106 46,111 3,207 7.47 899 58.83 0.0095
2019-02-14 2018-12-31 13F APELLIS PHARMACEUTICALS COM 03753U106 42,904 21,804 103.34 566 50.93 0.0066
2018-11-14 2018-09-30 13F APELLIS PHARMACEUTICALS COM 03753U106 21,100 21,100 375 0.0045
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F APELLIS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-14 2025-09-30 13F APELLIS PHARMACEUTICALS COM Call 27,000 611 n/a n/a n/a
2024-05-15 2024-03-31 13F APELLIS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-14 2023-12-31 13F APELLIS PHARMACEUTICALS COM Call 15,000 898 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-05-15 2024-03-31 13F APELLIS PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-14 2023-12-31 13F APELLIS PHARMACEUTICALS COM Put 15,000 898 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.